

Liver Cancer: Improving Standard Diagnosis and Therapy

Guest Editors:

Dr. Ryota Masuzaki

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan

Dr. Tatsuo Kanda

Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Itabashi, Tokyo 173-8610, Japan

Deadline for manuscript submissions:

closed (10 April 2023)


Message from the Guest Editors

Liver cancer is a common malignancy worldwide, responsible for 5% of all newly diagnosed cancers.

The treatment option is guided based on the Barcelona Clinic Liver Cancer (BCLC) stages. For BCLC A, curative treatments such as radiofrequency ablation, surgical resection, and liver transplantation are indicated. Long-term survival rates of liver cancer patients remain poor, and how to preserve liver function reservoir and how to prevent recurrence of tumor are challenging tasks in the field. For the patients with BCLC B and C, transarterial chemoembolization or systemic chemotherapy is indicated. Newly developed molecular targeted agents (MTA) and immuno-oncology drugs are now available. Several anti-programmed death receptor-1, anti-programmed cell death ligand 1, and anti-cytotoxic lymphocyte antigen 4, are currently being investigated and their combinations with MTA are expected to bring better clinical outcomes. Direct and indirect biomarkers for the prediction and stratification are being vigorously investigated and are expected to be applied in daily clinical practice.

In this Special issue, we focus on recent basic and clinical cancer research into liver cancer.





Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[@Cancers_MDPI](https://twitter.com/Cancers_MDPI)